NICE have issued a draft guidance against the use of Spinraza® (nusinersen) as an NHS treatment for spinal muscular atrophy.
A valuable cache of brain cancer biomedical data, termed REMBRANDT, has been made freely accessible to researchers worldwide.
Accelerator has announced the launch of Magnolia Neurosciences, a company developing a new class of neuroprotective therapies for patients.
In the largest study of its kind, researchers have revealed that individuals who exercise report having fewer days of poor mental health than those who do not exercise.
Results from the Phase III TOLEDO study suggests that treatment of Parkinson’s with apomorphine increases periods of good motor control and reduces periods when Parkinson’s disease medications are ineffective.
Researchers have reported successful creation of spinal cord neural stem cells that could provide a scalable source of replacements cells for spinal cord injuries.
In a recent study, a scientist has revealed the development of a stem cell model to assess possible treatments for a rare nervous system disorder called Alexander disease.
Novartis has announced that the EMA has granted license for the use of Aimovig® (erenumab) for the prevention of migraine in adults.
The US FDA has accepted for filing a resubmission of the New Drug Application for cladribine tablets by Merck; this could be a potential treatment for patients with relapsing forms of multiple sclerosis.